Wockhardt Limited
WOCKPHARMA
Kedudukan dalam Saham
#4518
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical... Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine. Further, the company offers delivery devices for insulin, including Dispopen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.
Harga Saham
$21.05
Modal Pasaran
$3.42B
Perubahan (1 hari)
0.04%
Perubahan (1 tahun)
34.95%
Negara
IN
Perdagangan Wockhardt Limited (WOCKPHARMA)
Kategori
Healthcare
Nisbah P/E bagi Wockhardt Limited (WOCKPHARMA)
Nisbah P/E pada October 2026 TTM: 77.72
Menurut laporan kewangan dan harga saham terkini Wockhardt Limited, nisbah P/E semasa (TTM) ialah 77.72. Pada akhir 2024, syarikat mempunyai nisbah P/E sebanyak -18.65.
Sejarah nisbah P/E bagi Wockhardt Limited dari 2004 hingga 2026
Nisbah P/E pada akhir setiap tahun
| Tahun | Nisbah P/E | Ubah |
|---|---|---|
| 2026 (TTM) | 77.72 | -116.21% |
| 2025 | -479.44 | 2,470.28% |
| 2024 | -18.65 | 370.29% |
| 2023 | -3.97 | -69.55% |
| 2022 | -13.02 | -279.55% |
| 2021 | 7.25 | -148.24% |
| 2020 | -15.04 | -46.47% |
| 2019 | -28.09 | 90.00% |
| 2018 | -14.78 | -66.46% |
| 2017 | -44.08 | -223.04% |
| 2016 | 35.83 | -34.90% |
| 2015 | 55.03 | 749.14% |
| 2014 | 6.48 | -57.04% |
| 2013 | 15.08 | -27.28% |
| 2012 | 20.74 | -51.12% |
| 2011 | 42.44 | -2,678.30% |
| 2010 | -1.65 | -82.28% |
| 2008 | -9.29 | -172.20% |
| 2007 | 12.87 | 6.50% |
| 2006 | 12.08 | -23.93% |
| 2005 | 15.89 | -19.25% |
| 2004 | 19.67 | 0.00% |
Nisbah P/E untuk syarikat serupa atau pesaing
| Syarikat | Nisbah P/E | Perbezaan Nisbah P/E | Negara |
|---|---|---|---|
| 24.47 | -68.51% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 223.52 | 187.59% |
US
|
Cara membaca nisbah P/E
Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.
Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.
Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.